Cargando…

Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review

BACKGROUND: Vedolizumab is a gut-selective anti-lymphocyte trafficking agent approved for the treatment of moderate to severely active inflammatory bowel disease (IBD: ulcerative colitis [UC] and Crohn’s disease [CD]). METHODS: A systematic literature review (SLR) of real-world studies was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Dipen, Martin, Stephan, Luo, Michelle, Ursos, Lyann, Lirio, Richard A, Kamble, Pravin, Wang, Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802433/ https://www.ncbi.nlm.nih.gov/pubmed/36777427 http://dx.doi.org/10.1093/crocol/otac020

Ejemplares similares

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease
por: Llano, Ernesto M, et al.
Publicado: (2021)

Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study
por: Hajjat, Temara M, et al.
Publicado: (2021)

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab
por: Harrington, Jill E, et al.
Publicado: (2020)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab
por: Chiorean, Michael, et al.
Publicado: (2020)

Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease
por: Wyant, Timothy, et al.
Publicado: (2021)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn’s Disease
por: Kwapisz, Lukasz, et al.
Publicado: (2022)

Impact of COVID-19 on Healthcare Resource Utilisation Among Patients with Inflammatory Bowel Disease in the USA
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data
por: Goss Sawhney, Tia, et al.
Publicado: (2023)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease
por: Horrigan, Jamie M, et al.
Publicado: (2023)

Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study
por: Kopylov, Uri, et al.
Publicado: (2023)

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
por: Schreiber, Stefan, et al.
Publicado: (2018)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2022)

Assessment of Vedolizumab Disease‐Drug‐Drug Interaction Potential in Patients With Inflammatory Bowel Diseases
por: Sun, Wan, et al.
Publicado: (2020)

Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil
por: Zaltman, Cyrla, et al.
Publicado: (2021)

Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
por: Oršić Frič, Vlasta, et al.
Publicado: (2023)

Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD
por: Click, Benjamin, et al.
Publicado: (2021)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe
por: Huynh, Lynn, et al.
Publicado: (2022)

Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence
por: Scribano, Maria Lia
Publicado: (2018)

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study
por: Eriksson, Carl, et al.
Publicado: (2021)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling
por: Uda, Akihito, et al.
Publicado: (2020)

Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn’s Disease
por: Dulai, Parambir S, et al.
Publicado: (2022)

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
por: Thomas, Pepijn W. A., et al.
Publicado: (2022)

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study
por: Dotti, Adriana Zanoni, et al.
Publicado: (2023)

Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study
por: Ghosh, Sabyasachi, et al.
Publicado: (2023)

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
por: Hibi, Toshifumi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_akepn3258fajnndr8o5o22vii8